Pharmacology and Pharmacotherapeutics: Finding New Avenues of Research

Sabitha Vadakedath¹, Vikram Godishala², Tarun Kumar Suvvari³ and Venkataramana Kandi^4,

¹Department of Biochemistry, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

²Department of Biotechnology, Ganapthi Degree College, Parakal, Telangana, India

³Dr. NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India

⁴Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Telangana, India

Cite this paper:
Sabitha Vadakedath, Vikram Godishala, Tarun Kumar Suvvari and Venkataramana Kandi. Pharmacology and Pharmacotherapeutics: Finding New Avenues of Research. American Journal of Pharmacological Sciences. 2021; 9(2):46-55. doi: 10.12691/ajps-9-2-1

Abstract

Pharmacology and pharmacotherapeutics assume increased significance in the treatment and management of human diseases. Also, it is evident from the current experiences of the novel Coronavirus pandemic, that specific therapeutic pharmacological agents are essential to successfully treat and manage patients. Having good knowledge of the pathogenesis of various diseases helps us in the direction towards the development of newer and improved pharmacotherapeutic agents. Also essential is to understand the anatomy, physiology, and functions of various organs of the human body like the eye, skin, kidneys, among others. Improved knowledge of the human immune responses to infections, inflammation, poisoning, drug reactions, and the agonistic and antagonistic activities of potential endogenous pharmacological molecules is necessary to discover newer pharmacological agents, improve health, and fight diseases.

Keywords:
pharmacology pharmacotherapeutics treatment management human diseases pathogenesis eye skin kidneys immune responses drug reactions

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Li S. (2015). Synthetic Bioactive Substances. In: Cheung P., Mehta B. (eds) Handbook of Food Chemistry. Springer, Berlin, Heidelberg.
[2]	Madhusudhan Kairamkonda, Vikram Godishala and Venkataramana Kandi. Identification of Newer Antimicrobial Agents: A Study of Invitro Antibacterial and Antifungal Activities of Leaf extracts of Medicinal Plant Aerva lanata (L.) Juss. ex Schult. American Journal of Microbiological Research. 2017; 5(3): 66-70.
[3]	Gemechu Berhanu, Dagmawit Atalel and Venkataramana Kandi. A Review of the Medicinal and Antimicrobial Properties of Carissa spinarum L.. American Journal of Biomedical Research. 2020; 8(2): 54-58.
[4]	Neelesh Deshpande, Raj kumar Das, Manohar muddeshwar, Vaishali Das, Sabitha Kandi and K V Ramana. Antioxidant Effects of Picrorhiza kurrooa Rhizome Extracts in Alcoholic Cirrhosis of Liver. American Journal of Pharmacological Sciences. 2015; 3(2):49-51.
[5]	Harry V. Synthetic medicines. Chem. Educ. 1930; 7: 1550.
[6]	Banerjee M, Khursheed R, Yadav AK, Singh SK, Gulati M, Pandey DK, Prabhakar PK, Kumar R, Porwal O, Awasthi A, Kumari Y, Kaur G, Ayinkamiye C, Prashar R, Mankotia D, Pandey NK. A Systematic Review on Synthetic Drugs and Phytopharmaceuticals Used to Manage Diabetes. Curr Diabetes Rev. 2020; 16(4): 340-356.
[7]	The Chemistry of Synthetic Drugs. JAMA. 1919; 73(13): 1004.
[8]	Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; 1: 134. Published 2010 Dec 8.
[9]	Vernon, Gervase. “Syphilis and Salvarsan.” The British journal of general practice: the journal of the Royal College of General Practitioners vol. 69, 682 (2019): 246.
[10]	Dawn Connelly. A history of aspirin. https://pharmaceutical-journal.com/article/infographics/a-history-of-aspirin.
[11]	Autacoid. https://www.sciencedirect.com/topics/immunology-and-microbiology/autacoid.
[12]	Ruiz-Capillas C, Herrero AM. Impact of Biogenic Amines on Food Quality and Safety. Foods. 2019; 8(2): 62. Published 2019 Feb 8.
[13]	Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26(1): 80-93.
[14]	Soltani M, Moradi Kashkooli F, Souri M, et al. Enhancing Clinical Translation of Cancer Using Nanoinformatics. Cancers (Basel). 2021; 13(10): 2481. Published 2021 May 19.
[15]	Zhou T, Yuan Z, Weng J, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021; 14(1): 24. Published 2021 Feb 12.
[16]	Agrahari V, Aulgur Z, Thukral S, Dhall N2, Conley R, Mitra AK. Recent Patents and Emerging Therapeutics on Ocular Inflammation and Allergy. Recent Pat Inflamm Allergy Drug Discov. 2017; 11(2): 92-106.
[17]	Agrahari V, Agrahari V, Mandal A, Pal D, Mitra AK. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2017 Oct; 14(10): 1145-1162.
[18]	Ness T, Hengel H. [Adverse ocular effects of vaccinations]. Ophthalmologe. 2016 Jul; 113(7): 615-22.
[19]	Ozkan J, Willcox MD. The Ocular Microbiome: Molecular Characterisation of a Unique and Low Microbial Environment. Curr Eye Res. 2019 Jul; 44(7): 685-694.
[20]	Ozkan J, Nielsen S, Diez-Vives C, Coroneo M, Thomas T, Willcox M. Temporal Stability and Composition of the Ocular Surface Microbiome. Sci Rep. 2017; 7(1): 9880. Published 2017 Aug 29.
[21]	Ding J, Yang N, Yan Y, Wang Y, Wang X, Lu L, Dong K. Rapamycin Inhibited Photoreceptor Necroptosis and Protected the Retina by Activation of Autophagy in Experimental Retinal Detachment. Curr Eye Res. 2019 Jul; 44(7): 739-745.
[22]	Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases. Pharmaceutics. 2018; 10(1): 28. Published 2018 Feb 27.
[23]	Choi SW, Kim J. Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review. Materials (Basel). 2018; 11(7): 1125. Published 2018 Jul 1.
[24]	Musgrave CSA, Fang F. Contact Lens Materials: A Materials Science Perspective. Materials (Basel). 2019; 12(2): 261. Published 2019 Jan 14.
[25]	Üstündağ Okur N, Çağlar EŞ, Siafaka PI. Novel Ocular Drug Delivery Systems: An Update on Microemulsions. J Ocul Pharmacol Ther. 2020 Jul/Aug; 36(6): 342-354.
[26]	Yu H, Wu W, Lin X, Feng Y. Polysaccharide-Based Nanomaterials for Ocular Drug Delivery: A Perspective. Front Bioeng Biotechnol. 2020 Dec 10; 8: 601246.
[27]	Buosi FS, Alaimo A, Di Santo MC, Elías F, García Liñares G, Acebedo SL, Castañeda Cataña MA, Spagnuolo CC, Lizarraga L, Martínez KD, Pérez OE. Resveratrol encapsulation in high molecular weight chitosan-based nanogels for applications in ocular treatments: Impact on human ARPE-19 culture cells. Int J Biol Macromol. 2020 Dec 15; 165(Pt A): 804-821.
[28]	Gupta R, Kumar A. Transfersomes: The Ultra-Deformable Carrier System for Non-Invasive Delivery of Drug. Curr Drug Deliv. 2021; 18(4): 408-420.
[29]	Begum G, Leigh T, Courtie E, Moakes R, Butt G, Ahmed Z, Rauz S, Logan A, Blanch RJ. Rapid assessment of ocular drug delivery in a novel ex vivo corneal model. Sci Rep. 2020 Jul 16; 10(1): 11754.
[30]	Formica ML, Legeay S, Bejaud J, Montich GG, Ullio Gamboa GV, Benoit JP, Palma SD. Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody - Bevacizumab - and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies. Mater Sci Eng C Mater Biol Appl. 2021 Feb; 119: 111398.
[31]	Chang MC, Kuo YJ, Hung KH, Peng CL, Chen KY, Yeh LK. Liposomal dexamethasone-moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing. Biomed Mater. 2020 Aug 10; 15(5): 055022.
[32]	Kiepurska N, Paluchowska E, Owczarek W, Szkultecka-Dębek M, Jahnz-Różyk K. The direct costs of drug-induced skin reactions. Ann Agric Environ Med. 2017 May 11; 24(2): 190-193.
[33]	Salinas T, Piquette-Miller M. Within Our Skin. Clin Pharmacol Ther. 2017 Jul; 102(1): 8-12.
[34]	Basra MK, Shahrukh M. Burden of skin diseases. Expert Rev PharmacoeconOutcomes Res. 2009 Jun; 9(3): 271-83.
[35]	Jain S, Barambhe M S, Jain J, Jajoo U N, Pandey N. Prevalence of skin diseases in rural Central India: A community-based, cross-sectional, observational study. J Mahatma Gandhi Inst Med Sci 2016; 21: 111-5
[36]	DeStefano GM, Christiano AM. The genetics of human skin disease. Cold Spring Harb Perspect Med. 2014;4(10):a015172. Published 2014 Oct 1.
[37]	Calabrese L, Malvaso D, Chiricozzi A, Tambone S, D'Urso DF, Guerriero C, Peris K. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert Opin Investig Drugs. 2020 Oct; 29(10): 1089-1098.
[38]	Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the Treatment of Atopic Dermatitis. Immunotargets Ther. 2020 Sep 29; 9: 151-156.
[39]	Parekh K, Mehta TA, Dhas N, Kumar P, Popat A. Emerging Nanomedicines for the Treatment of Atopic Dermatitis. AAPS PharmSciTech. 2021 Jan 24; 22(2): 55.
[40]	McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother. 2020 Nov; 21(16): 2041-2056.
[41]	Vadakedath S, Kandi V. Dialysis: A Review of the Mechanisms Underlying Complications in the Management of Chronic Renal Failure. Cureus. 2017; 9(8):e1603. Published 2017 Aug 23.
[42]	Cho KS, Ko IK, Yoo JJ. Bioactive Compounds for the Treatment of Renal Disease. Yonsei Med J. 2018; 59(9): 1015-1025.
[43]	Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., Shahinfar S., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
[44]	Brem AS, Gong R. Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease. Clin Sci (Lond). 2015; 128(9): 527-535.
[45]	Wan S, Wan S, Jiao X, Cao H, Gu Y, Yan L, Zheng Y, Niu P, Shao F. Advances in understanding the innate immune-associated diabetic kidney disease. FASEB J. 2021 Feb; 35(2): e21367.
[46]	Abdelhafiz AH. Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. Drugs Aging. 2020 Aug; 37(8): 567-584.
[47]	Hartman RE, Rao PSS, Churchwell MD, Lewis SJ. Novel therapeutic agents for the treatment of diabetic kidney disease. Expert Opin Investig Drugs. 2020 Nov; 29(11): 1277-1293.
[48]	Dwyer KM, Kishore BK, Robson SC. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease. Nat Rev Nephrol. 2020 Sep; 16(9): 509-524.
[49]	Chen Z, Peng H, Zhang C. Advances in kidney-targeted drug delivery systems. Int J Pharm. 2020 Sep 25; 587: 119679.
[50]	Natesan V, Kim SJ. Diabetic Nephropathy - a Review of Risk Factors, Progression, Mechanism, and Dietary Management. Biomol Ther (Seoul). 2021 Jul 1; 29(4): 365-372.
[51]	Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007 Aug; 138(4): 407-21.
[52]	Arthur W. Nienhuis. Development of gene therapy for blood disorders: an update. Blood 2013 122: 1556-1564.
[53]	Shah NM, Chong SE, Yusoff SM, et al. Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience. BMC Hematol. 2018; 18: 34. Published 2018 Nov 23.
[54]	Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J. 2020 Aug 22; 10(8): 84.
[55]	Padrnos L, Mesa R. Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. Expert Opin Investig Drugs. 2020 Aug; 29(8): 809-817.
[56]	Norrby SR. Infectious disease emergencies: role of the infectious disease specialist. Clin Microbiol Infect. 2005 Apr; 11 Suppl 1: 9-11.
[57]	Nigama A, Gupta D, Sharma A. Treatment of infectious disease: Beyond antibiotics. Microbiological Research 2014; 169: 643-651
[58]	FDA Approved Drugs for Infections and Infectious Diseases. https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-and-infectious-diseases. Last Accessed 01st April 2021.
[59]	World health organization (WHO). Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Last Accessed 01st April 2021.
[60]	Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology. 2018 Jan; 23(1): 36-45.
[61]	Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021 Jan; 57(1): 106220.
[62]	Mota Fernandes C, Del Poeta M. Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies. Expert Rev Anti Infect Ther. 2020 Nov; 18(11): 1083-1092.
[63]	Bedair A, Mansour FR. Insights into the FDA 2018 New Drug Approvals. Curr Drug Discov Technol. 2021; 18(2): 293-306.
[64]	Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013; 3(9): a015487. Published 2013 Sep 1.
[65]	Conibear AC, Pötgens AJG, Thewes K, Altdorf C2, Hilzendeger C, Becker CFW. Synthetic Cancer-Targeting Innate Immune Stimulators Give Insights into Avidity Effects. Chembiochem. 2018 Mar 2; 19(5): 459-469.
[66]	Casi G, Neri D. Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. J Med Chem. 2015 Nov 25; 58(22): 8751-61.
[67]	About Immunosuppressant Drugs. https://www.healthline.com/health/immunosuppressant-drugs#treatment. Last Accessed 01st August 2019.
[68]	Crane E, List A. Immunomodulatory drugs. Cancer Invest. 2005; 23(7): 625-34.
[69]	Hossain IT, Sanghi P, Manzouri B. Pharmacotherapeutic management of atopic keratoconjunctivitis. Expert Opin Pharmacother. 2020 Oct; 21(14): 1761-1769.
[70]	Pressman P, Clemens R, Sahu S, Hayes AW. A review of methanol poisoning: a crisis beyond ocular toxicology. Cutan Ocul Toxicol. 2020 Sep; 39(3): 173-179.
[71]	Bajracharya SR, Prasad PN, Ghimire R. Management of Organophosphorus Poisoning. J Nepal Health Res Counc. 2016 Sep; 14(34): 131-138.
[72]	Poisoning. http://www.healthcommunities.com/poisoning/treatment.shtml. Last Accessed 01st August 2019.
[73]	Schaper A. [Charcoal, cocaine and rattlesnakes: evidence-based treatment of poisoning]. Anaesthesist. 2013 Oct; 62(10): 824-31.
[74]	Schaper A, Ceschi A, Deters M, Kaiser G. Of pills, plants, and paraquat: the relevance of poison centers in emergency medicine. Eur J Intern Med. 2013 Mar; 24(2): 104-9.
[75]	Glennon RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv Pharmacol. 2014; 69: 581-620.
[76]	Hsieh CY, Tsai TF. Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review. Clin Drug Investig. 2020 Oct; 40(10): 915-926.
[77]	Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. Arterioscler Thromb Vasc Biol. 2021 Jan; 41(1): 141-152.
[78]	Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol. 2020 Oct; 94(10): 3381-3407.
[79]	Holland EG, Degruy FV. Drug-induced disorders. Am Fam Physician. 1997 Nov 1; 56(7): 1781-8, 1791-2.
[80]	Bhatti AB, Usman M, Kandi V. Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges with Compliance to Antiretroviral Therapy. Cureus. 2016; 8(3): e515. Published 2016 Mar 1.
[81]	Ramana K V, Rao R. Human immunodeficiency virus disease management in highly active antiretroviral therapy era: A comprehensive review. Ann Trop Med Public Health 2013; 6: 5-9.
[82]	Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons With Co-Occurring Disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 42.) 9 Substance-Induced Disorders. Available from: https://www.ncbi.nlm.nih.gov/books/NBK64178/.
[83]	Davies, D M. J Adverse Drug Reaction Bulletin 1985; 112: 1416-419.
[84]	Janina Maria Sørensen. Herb–Drug, Food–Drug, Nutrient–Drug, and Drug–Drug Interactions: Mechanisms Involved and Their Medical Implications. The Journal of Alternative and Complementary Medicine. 2004; 8.
[85]	Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, Di Rosa F, Andrade R, Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. Int J Mol Sci. 2021 Apr 27; 22(9): 4557.
[86]	Sharifzadeh S, Mohammadpour AH, Tavanaee A, Elyasi S. Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review. Eur J Clin Pharmacol. 2021 Mar; 77(3): 275-289.
[87]	Zipser RD, Laffi G. Prostaglandins, thromboxanes and leukotrienes in clinical medicine. West J Med. 1985; 143(4): 485-497.
[88]	Dominguez-Meijide A, Villar-Cheda B, Garrido-Gil P, Sierrra-Paredes G, Guerra MJ, Labandeira-Garcia JL. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA. Neuropharmacology. 2014 Jan; 76 Pt A: 156-68.
[89]	Pes R, Godar SC, Fox AT, et al. Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release. Neuropharmacology. 2017; 114: 77-87.
[90]	Martini A, Dal Lago D, Edelstyn NMJ, Salgarello M, Lugoboni F, Tamburin S. Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies. Front Neurol. 2018; 9: 1018. Published 2018 Dec 4.
[91]	Miller SB. Prostaglandins in health and disease: an overview. Semin Arthritis Rheum. 2006 Aug; 36(1): 37-49.
[92]	Higgins AJ. Eicosanoids in health and in disease: an appraisal. Vet Q. 1985 Jan; 7(1): 44-59.
[93]	Claar D, Hartert TV, Peebles RS Jr. The role of prostaglandins in allergic lung inflammation and asthma. Expert Rev Respir Med. 2015; 9(1): 55-72.
[94]	Calder PC. Eicosanoids. Essays Biochem. 2020 Sep 23; 64(3): 423-441.
[95]	Meek IL, Van de Laar MA, E Vonkeman H. Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals (Basel). 2010; 3(7): 2146-2162. Published 2010 Jul 7.
[96]	Yazdanian N, Mozafarpoor S, Goodarzi A. Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review. Dermatol Ther. 2021 Jan; 34(1): e14669.
[97]	Lo KJ, Ko YC, Hwang DK, Liu CJ. The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues-A systemic review and meta-analysis. PLoS One. 2020 Sep 14; 15(9): e0239233.
[98]	Ma Y, Hong FF, Yang SL. Role of prostaglandins in rheumatoid arthritis. Clin Exp Rheumatol. 2021 Jan-Feb; 39(1): 162-172. Epub 2020 Jul 21. PMID: 32828139.
[99]	Gilman KE, Limesand KH. The complex role of prostaglandin E2-EP receptor signaling in wound healing. Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1; 320(3): R287-R296.
[100]	Damase-Michel C, Lacroix I, Hurault-Delarue C, Beau AB, Montastruc JL; les partenaires d’EFEMERIS. [Drug in pregnancy: studies in the French database EFEMERIS]. Therapie. 2014 Jan-Feb; 69(1): 91-100.
[101]	Wimmer S, Neubert A, Rascher W. The Safety of Drug Therapy in Children. Dtsch Arztebl Int. 2015; 112(46): 781-787.
[102]	Aydoğan BB, Yıldırım F, Zerman A, Gönderen K, Türkoğlu M, Aygencel G. Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients? Aging Clin Exp Res. 2018 Jun; 30(6): 573-580.
[103]	Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015; 39(7): 512-519.
[104]	Greene MF. FDA drug labeling for pregnancy and lactation drug safety monitoring systems. Semin Perinatol. 2015 Nov; 39(7): 520-3.
[105]	Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016; 7(5): 346-353.